OVS (OVS) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
8 Jul, 2026Executive summary
Q3 2024 net sales rose 12.8% year-over-year to €414.7 million, with robust like-for-like growth and strong performance across all brands, especially in the women’s segment.
Adjusted EBITDA increased 31.7% in Q3 2024 to €46.2 million, and profit before tax grew 70.9%, driven by successful merchandising and brand initiatives.
For the first nine months of 2024, net sales reached €1,176.3 million, up 6.7% year-over-year, with adjusted EBITDA up 11.3% to €135.2 million.
Upim posted record results since acquisition, outperforming OVS year-to-date; Stefanel showed strong recovery in H2 due to new creative leadership.
Strategic focus on women’s segment, new house brands, and beauty category drove increased store traffic and customer base.
Financial highlights
Q3 2024 adjusted EBITDA margin improved to 11.1% from 9.5% in Q3 2023; EBIT margin rose to 7.0% from 5.1%.
Nine-month adjusted EBITDA margin reached 11.5%, up from 11.0% in 9M 2023; EBIT margin increased to 7.3%.
Last twelve months net sales and EBITDA reached €1,609 million and €196 million, respectively, with a 12.2% EBITDA margin.
EBITDA margin above 12% for the full year, with OVS close to 13% and Upim above 10%.
Cash flow before dividends and treasury share purchases increased by €8.0 million year-over-year, driven by EBITDA growth.
Outlook and guidance
Q4 and full-year 2024 sales and EBITDA are expected to align with or slightly exceed 2023, with cash generation in line with last year.
Guidance for full-year CapEx is €90–95 million, with ordinary CapEx expected to decrease by €15–20 million in coming years.
Growth drivers for next year include easier H1 comparison, new projects (Les Copains, sport, beauty), Goldenpoint consolidation, and international expansion.
Interest confirmed in acquiring part of Conbipel's retail network, with further consolidation opportunities being explored.
Latest events from OVS
- Sales and margins rose in H1 2024, with strong outlook and expanded buyback.OVS
Q2 202524 Jun 2026 - Record H1 2025 sales and profit growth, led by women's, beauty, and Goldenpoint integration.OVS
Q2 202624 Jun 2026 - Net sales up 12.1% and organic EBITDA up 27.1%, with improved leverage and strong outlook.OVS
Q1 202718 Jun 2026 - Record sales, profit, and cash flow growth drive a 27% dividend hike and strong 2026 outlook.OVS
Q4 202617 Apr 2026 - Q1 sales and margins rose, with strong brand momentum and a positive outlook for 2024.OVS
Q1 20253 Feb 2026 - Sales up 6.2%, margins and cash flow improved, with higher dividend and buyback ahead.OVS
Q4 202523 Dec 2025 - Sales and EBITDA up, leverage improved, and outlook remains positive for year-end.OVS
Q3 202618 Dec 2025 - Q1 sales grew 0.6% to €354.4m; Goldenpoint synergies and Q2 momentum support a positive outlook.OVS
Q1 202614 Nov 2025